Provided by Tiger Fintech (Singapore) Pte. Ltd.

Purple Biotech Ltd.

2.80
-0.0400-1.41%
Volume:7.74K
Turnover:21.81K
Market Cap:7.42M
PE:-0.63
High:2.86
Open:2.83
Low:2.76
Close:2.84
Loading ...

Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer

GlobeNewswire
·
16 Apr

Purple Biotech Q4 EPADS $(0.26)

Benzinga
·
10 Mar

Press Release: Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Dow Jones
·
10 Mar

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets

GlobeNewswire
·
05 Mar

Purple Biotech Ltd expected to post a loss of $1.80 a share - Earnings Preview

Reuters
·
28 Feb

Purple Biotech Moves NT219 Into Phase 2 Trial Aimed at Overcoming Tumor Resistance in Head, Neck Cancer Therapies

MT Newswires Live
·
18 Feb

Purple Biotech advances NT219 into Phase 2 head, neck cancer trial

TIPRANKS
·
18 Feb

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

GlobeNewswire
·
18 Feb

Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform

GlobeNewswire
·
03 Feb

Purple Biotech Secures $2.8 Million for Oncology Advancements

TIPRANKS
·
05 Dec 2024

ADRs End Lower; Purple Biotech Ltd. Declines 27%

Dow Jones
·
05 Dec 2024

Purple Biotech Signs Securities Purchase Agreement

TIPRANKS
·
05 Dec 2024

Purple Biotech Secures $2.8 Million Through ADS Offering

TIPRANKS
·
04 Dec 2024

PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy

Zacks
·
04 Dec 2024

ADRs Advance; Purple Biotech Ltd. Climbs 150%

Dow Jones
·
03 Dec 2024

Economic Data in Focus as US Equity Futures Waver Pre-Bell

MT Newswires Live
·
02 Dec 2024

Purple Biotech Shares Jump on Positive Phase 2 Cancer Drug Study Results

Dow Jones
·
02 Dec 2024

Purple Biotech Reports Positive Phase 2 Study Results for CM24 Plus Nivolumab and Chemotherapy in Patients With Pancreatic Cancer

MT Newswires Live
·
02 Dec 2024

Purple Biotech Price Target Maintained With a $33.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Nov 2024

Purple Biotech Ltd expected to post a loss of $3.30 a share - Earnings Preview

Reuters
·
15 Nov 2024